Federal court issues TRO blocking My Doctor Suggests, GP Silver and their owner, Gordon Pedersen, from continuing to sell or distribute silver colloidal products for the diagnosis, cure, mitigation, treatment or prevention of any disease.
Federal prosecutors allege my doctor suggests Alkaline Structured Silver was promoted with claims including "will destroy all forms of viruses, it will protect people from the Coronavirus.”
Federal prosecutors' expectations that some US businesses will attempt to fraudulently capitalize on consumer fear about COVID-19 are being met, most recently by another firm peddling silver colloidal dietary supplements as a remedy.
The US District Court for Utah on 27 April issued a temporary restraining order blocking My Doctor Suggests LLC,...
Explore how consumer health is evolving. On the go.
David Ridley hosts in-depth conversations with industry leaders.
The Supreme Court’s 6-3 ruling is expected to have a minimal impact on drug approvals and other scientific determinations, but matters steeped in the interpretation of regulation and statute, such as marketing exclusivity, could face a heightened risk of challenge, legal experts say.
Whether called “dark patterns,” “shady” online marketing practices, or simply deception on the internet, the issue has taken on high importance at the US Federal Trade Commission and is being tackled by new laws in a growing number of states. Amin Talati Wasserman partner Lauren Aronson discusses in this interview with HBW Insight.
BBB National Programs found FTC’s proposed Trade Regulation Rule on the Use of Consumer Reviews and Testimonials largely effective with some certainty on whether product reviews or customer testimonials are violations of its false advertising standards. But it =expects some clarifications may come in final rule.
Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.
Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.
In this installment of HBW Insight’s “Inside Regulatory Affairs” series, we hear from Sharee Crumbey and Monica Sharda, regulatory affairs specialists at The Honest Company, about the mounting challenges and rewards of the job.